Immunostaining for SYT protein discriminates synovial sarcoma from other soft tissue tumors: analysis of 146 cases

He, Rui; Patel, Rajiv M.; Alkan, Serhan; Hammadeh, Rasheed; Weiss, Sharon W.; Goldblum, John R.; Venkataraman, Girish; Baila, Horea

doi:10.1038/modpathol.3800766

Cited by 28 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 Recently, an antibody to the SS18 gene product has been shown to be sensitive for identification of synovial sarcomas, but it is not specific and has not found general application. 22 MPNSTs have focal nuclear positivity for S100 protein in up to 67% of cases, which correlates with ultrastructural evidence of Schwann cell differentiation. 23 Table 1.…”

Section: Malignant Spindle Cell Neoplasmsmentioning

confidence: 73%

“…Synovial sarcomas are characterized by a specific chromosomal translocation t(X;18)(p11.2;q11.2), which results in fusion of the SS18 ( SYT ) gene from chromosome 18 with one of several variants of the SSX gene on the X chromosome 21 . Recently, an antibody to the SS18 gene product has been shown to be sensitive for identification of synovial sarcomas, but it is not specific and has not found general application 22 …”

Section: Spindle Cell Tumoursmentioning

confidence: 99%

See 1 more Smart Citation

Immunohistochemistry in diagnosis of soft tissue tumours

Fisher

2010

Histopathology

View full text Add to dashboard Cite

Immunohistochemistry in soft tissue tumours, and especially sarcomas, is used to identify differentiation in the neoplastic cells. In some cases, specific antigens are expressed; however, an initial panel of antibodies is often required in order to establish the broad lineage, with a subsequent, more focused, panel to allow classification. Immunohistochemical evaluation must be employed with the clinical picture, the morphology, and, when necessary, other ancillary techniques such as molecular genetics and cytogenetics. Whereas some diagnoses are evident on morphology, many soft tissue neoplasms are seen microscopically as spindle cell, epithelioid cell, small round cell or pleomorphic tumours that need to be further characterized. This article reviews selected applications of immunohistochemistry in the diagnosis of each of the principal morphological groups, concentrating on areas of most use in daily practice.

show abstract

Section: Malignant Spindle Cell Neoplasmsmentioning

confidence: 73%

Section: Spindle Cell Tumoursmentioning

confidence: 99%

Immunohistochemistry in diagnosis of soft tissue tumours

Fisher

2010

Histopathology

View full text Add to dashboard Cite

show abstract

“…TLE1 is a transcriptional corepressor overexpressed in synovial sarcoma; diffuse nuclear staining with anti-TLE1 antibody is seen in SS, whereas MPNST is typically negative [ 139 ]. Determination of SYT status by immunohistochemistry may be similarly helpful [ 140 ], being consistently positive in SS, paralleling the expected SYT-associated translocations demonstrable by FISH [ 141 ] or other molecular modalities; SYT alterations, in contradistinction, are not expected in MPNSTs. Leiomyosarcoma and solitary fi brous tumor are two other mimics; happily, immunopositivity for smooth muscle actin (SMA) and diffuse CD34 positivity, respectively, reliably separate these spindle cell neoplasms from MPNST.…”

Section: Differential Diagnosismentioning

confidence: 93%

Malignant Tumors of Peripheral Nerves

Kao

Parham

Fuller

2014

Pediatric Malignancies: Pathology and Imaging

View full text Add to dashboard Cite

Malignant peripheral nerve sheath tumors (MPNST) represent a group of malignant spindle cell sarcomas with evidence of nerve sheath differentiation and/or arising from a peripheral nerve. Tumors showing origin from epineurial connective tissue or vascular structures are not considered to represent MPNST. Older/prior terminology for MPNST includes malignant neurilemmoma, malignant schwannoma, neurofi brosarcoma, and neurogenic sarcoma [ 1 ]. A number of histologic subtypes have been described. The majority are high grade aggressive sarcomas that show a strong tendency for local recurrence and metastases despite aggressive therapeutic measures [ 2 ]. Clinical Features and EpidemiologyThere is a strong association between MPNST and Neurofi bromatosis Type 1 (NF1), with 50 % of all MPNSTs arising within this patient population [ 3 ]. Approximately 10 % of individuals with NF1 will develop an MPNST over their lifetime, most of these tumors representing malignant degeneration occurring within preexisting plexiform neurofi bromas. One study of 476 NF1 patients documented a strong association between the presence of subcutaneous neurofi bromas and internal plexiform neurofi bromas, with an even stronger correlation between the presence of internal plexiform neurofi bromas and MPNST [ 4 ]. The remainder of MPNSTs will arise de novo, approximately 5-10 % representing radiation-induced sarcomas [ 1 ]. There is no particular gender predilection, and MPNSTs have been documented throughout a wide age range including children and the elderly. The majority however tend to present in adults with a median age in the mid 40s [ 5 ]. MPNSTs arising in the NF1 population tend to present up to a decade earlier, and these patients' tumors also tend to be larger [ 3 , 6 ].The majority of MPNST arise from larger peripheral nerves or within deep soft tissues, the most frequent sites including brachial plexus, sciatic, and paraspinal nerves, proximal upper and lower extremities, and buttock regions [ 5 ]. They have also been documented in a wide variety of locations throughout the body. Well over 50 cases of spinal MPNST have been reported [ 7 -13 ]. No particular spinal level is preferentially involved, and interestingly a significant proportion of spinal MPNST exhibit rhabdomyoblastic elements (Malignant Triton Tumor; see histologic description below) [ 14 -17 ]. MPNST represents one of the most aggressive tumors that may involve structures of the head and neck region [ 6 ]. It may arise from cranial nerves, particularly the vestibular [ 18 ], vagus [ 18 ], facial [ 18 , 19 ], and trigeminal [ 19 , 20 ]. Other sites include not only brachial plexus [ 21 ], but also scalp and bony structures (base of skull [ 22 -25 ], sinuses [ 26 , 27 ], and bones of the jaw) [ 28 , 29 ]

show abstract

“…TLE1 protein is also involved in the Wnt/β-catenin signaling pathway associated with SS, where it replaces TLE1-TCT/LEF complexes that repress transcription [18][19][20]. Genetic studies have identified TLE1 as a robust biomarker for differentiating SS from its histologic identicals [21][22][23].…”

Section: Introductionmentioning

confidence: 99%